Citadel Advisors
LIMN

Citadel Advisors’s Liminatus Pharma LIMN Stock Holding History

Citadel Advisors’s Portfolio LIMN Stock Details LIMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.19K Sell
1,122
-12,428
-92% -$107K ﹤0.01% 13527
2026
Q1 		$116K Buy
13,550
+12,131
+855% +$324K ﹤0.01% 11885
2025
Q4 		$43.3K Buy
+1,419
New +$78.8K ﹤0.01% 12100

Other funds holding LIMN

CCA
Cygnus Capital Advisors Atlanta, Georgia $147M AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Personalized Indexing Management
Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return

Citadel Advisors's LIMN Position: Q2 2026 in Review

Citadel Advisors reduced its Liminatus Pharma (LIMN) stake by 92% in Q2 2026, selling an estimated $107K and leaving 1,122 shares worth $6.19K. The position accounts for ﹤0.01% of the portfolio, ranked #13527.

Citadel Advisors first reported a position in LIMN in Q4 2025 and has held it in 3 quarters since. The position peaked at $116K in Q1 2026. 14 funds tracked by Wall St. Rank hold LIMN as of Q2 2026.

  • Citadel Advisors held 1,122 shares of Liminatus Pharma worth $6.19K as of Q2 2026.
  • Citadel Advisors sold 12,428 Liminatus Pharma shares in Q2 2026, an estimated $107K.
  • Liminatus Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13527 holding.
  • Citadel Advisors first reported a position in Liminatus Pharma in Q4 2025 and has held it in 3 quarters since.
  • Citadel Advisors's Liminatus Pharma position peaked at $116K in Q1 2026.
  • 14 funds tracked by Wall St. Rank held Liminatus Pharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.